Long-term efficacy and safety of addition of carboplatin with or without veliparib to standard neoadjuvant chemotherapy in triple-negative breast cancer: 4-year follow-up data from BrighTNess, a randomized phase III trial

C. E. Geyer, W. M. Sikov, J. Huober, H. S. Rugo, N. Wolmark, J. O'Shaughnessy, D. Maag, M. Untch, M. Golshan, J. Ponce Lorenzo, O. Metzger, M. Dunbar, W. F. Symmans, P. Rastogi, J. H. Sohn, R. Young, G. S. Wright, C. Harkness, K. McIntyre, D. YardleyS. Loibl

Research output: Contribution to journal › Article › peer-review

90 Scopus citations

Fingerprint

Dive into the research topics of 'Long-term efficacy and safety of addition of carboplatin with or without veliparib to standard neoadjuvant chemotherapy in triple-negative breast cancer: 4-year follow-up data from BrighTNess, a randomized phase III trial'. Together they form a unique fingerprint.

Medicine & Life Sciences